- Home
- SKE vs GLPG Comparison
SKE vs GLPG Comparison
Compare SKE & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKE | GLPG |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SKE | GLPG |
|---|---|---|
| Price | $25.46 | $32.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 839.6K | 86.8K |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | N/A | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $8.53 | $22.36 |
| 52 Week High | $26.05 | $37.78 |
Technical Indicators
Market Signals| Indicator | SKE | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 59.52 |
| Support Level | $23.97 | $30.73 |
| Resistance Level | $24.98 | $33.23 |
| Average True Range (ATR) | 1.14 | 0.57 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 85.34 | 81.64 |
Price Performance
Historical ComparisonAbout SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.